Skip to main content

Table 1 Characteristics of studies included in the final analyses

From: Optimal cutoff of pretreatment neutrophil-to-lymphocyte ratio in head and neck cancer patients: a meta-analysis and validation study

  Study (First Author) Publication year No. of subject NLR cutoff Stage Index of tumor Follow-up (mo) Outcome HR extraction Multivariate adjustment
1 He [28] 2012 1410 2.17 I-IV Pharynxa 41 OS, PFS Reported Yes
2 Millrud [29] 2012 20 6 I-IV Othersb 24 OS Reported No
3 Fang [30] 2013 226 2.44 I-IV Oral cavity   OS, DFS Reported No
4 Rassouli [18] 2013 273 4.27   Others 45 DFS Reported No
5 Jin [31] 2014 229 3.6 III, IV Pharynx   OS Reported Yes
6 Young [32] 2014 249 5   Pharynx 46 OS Reported No
7 Haddad [33] 2015 46 5 III, IV Others 34 OS, DFS Reported No
8 Rachidi [34] 2015 543 4.39 I-IV Others 64 OS Reported Yes
9 Salim [35] 2015 79 2.93 I-IV Others   OS, PFS Reported No
10 Selzer [36] 2015 170 5 I-IV Others   OS Reported Yes
11 Song [37] 2015 146 2.3   Pharynx 26 OS Reported No
12 Sun [19] 2015 251 2.7 I-IV Pharynx 50 OS, PFS Reported Yes
13 Tu [16] 2015 141 2.17 I-IV Larynx 51 OS, DFS Reported Yes
14 Charles [14] (1)c 2016 76 5 I-IV Pharynx 29 OS, DFS Reported Yes
15 Charles [14] (2)c 2016 69 5 I-IV Others 29 OS, DFS Reported Yes
16 Chua [38] 2016 380 3 I-IV Pharynx   OS, DFS Reported Yes
17 Fu [39] 2016 420 2.59 III, IV Larynx   OS Reported Yes
18 Ikeguchi [40] 2016 59 5 III, IV Pharynx 38 OS Reported Yes
19 Kano [41] 2016 285 1.92 I-IV Others 63 OS, DFS Reported Yes
20 Kim [42] 2016 104 3 III, IV Others 39 OS, DFS Reported Yes
21 Moon [43] 2016 153 3 I-IV Others 39 OS, PFS Reported Yes
22 Nakashima [15] 2016 124 2.4 III, IV Pharynx 47 OS, DFS Reported Yes
23 Wong [17] 2016 140 3.1 I-IV Larynx 41 OS, DFS Reported Yes
24 Zeng [44] 2016 115 3 III, IV Larynx 45 OS, PFS Reported Yes
25 Turri_Zanoni [45] 2017 215 5.56   Others 51 OS, DFS Reported Yes
  1. NLR neutrophil to lymphocyte ratio, PLR platelet to lymphocyte ratio, OS overall survival, DFS disease free survival, PFS progression free survival
  2. ainclude following tumor subsite; nasopharynx, oropharynx and hypopharynx
  3. binclude following tumor subsite; nasal cavity or not specified
  4. cA paper by Charles et al. had clinical data with two groups; oropharyngeal cancer and non-oropharyngeal cancer. We divided the results into two independent sets and employed these results separately into our analyses, named as Charles (1) and Charles (2)